function. 2 Genes that are known to be abnormally hypermethylated in ALL are calcitonin, ER, p15, p16, HIC-1, p73, E-cadherin, promoter-associated CpG islands, Wnt and Src among others. [5] [6] [7] In proliferating cells, DNA methylation is critically dependent on continued expression of DNA methyltransferases. Moreover, several groups have recently shown that aberrant DNA methylation is an independent prognostic factor for disease-free survival, overall survival and treatment resistance. 8, 9 The cytosine analogue 5-aza-2 0 -deoxyazacytidine 2 0 -deoxy-5-azacytidine (decitabine) is an S-phase-specific inhibitor of DNA methyltransferase with a hypomethylating activity. Depending on dose, this drug has a dual mechanism. At higher doses, decitabine inhibits cell proliferation through nonreversible covalent linking with DNA methyltransferase and blocking of DNA synthesis. At lower doses, decitabine induces hypomethylation, thereby promoting cell differentiation, reexpression of tumour suppressor genes, stimulation of immune mechanisms and suppression of tumour growth.
In myeloid malignancies, decitabine have shown efficacy in clinical practice in the treatment of MDS and AML. In fact, the US Food and Drug Administration (FDA) has approved decitabine for the treatment of patients with previously treated, untreated, de novo and secondary MDS, including chronic myelomonocytic leukemia.
In contrast, although in vitro studies in ALL cells have shown that these drugs can reactivate gene expression and restore the normal protein levels, to our knowledge, there is not clinical experience reported so far. The present case is the first clinical evidence about the usefulness of decitabine to treat refractory ALL. Likewise, our experience has shown that decitabine can be used in paediatric patients and is able to induce CR in heavily pretreated patients with acceptable side effects allowing a rapid accomplishment of BM transplantation. All this suggests that this drug should be investigated in refractory ALL. TET2 (TET oncogene family member 2) is a putative tumor suppressor gene located at chromosome 4q24. 1 Delhommeau et al. 1 were the first to report the occurrence of TET2 mutations in myeloproliferative neoplasms (MPN); the authors discovered frameshift, nonsense and missense TET2 mutations in approximately 14% of 181 patients with JAK2V617F-positive polycythemia vera, essential thrombocythemia or primary myelofibrosis (PMF). We subsequently confirmed this observation in a recent study of 239 patients and reported mutational frequencies of B16, B5 and B17% in polycythemia vera, essential thrombocythemia and PMF, respectively. 2 In the latter study, TET2 mutations were seen in both JAK2V617F-positive (B17%) and negative (B7%) cases and their frequency was similar in chronic and advanced phase disease. 2 In another recent Leukemia paper, 3 we reported an even higher TET2 mutational frequency of 29% in systemic mastocytosis (SM), a disease that is also formally classified as MPN. 4 In this study, we looked for the presence of TET2 mutations in myeloid malignancies other than MPN, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), 'MDS/MPN' and acute myeloid leukemia (AML). We have also included some cases with MPN, unclassifiable (MPN-U). 4 After approval by the Mayo Clinic institutional review board, study patients were selected on the basis of availability of stored bone marrow cells for DNA extraction and mutation analysis. Diagnoses were established on the basis of 2001 World Health Organization (WHO) criteria. 5 Mutation screening for JAK2V617F (reverse transcription-PCR) was performed using bone marrow-derived cells, according to the earlier published methods. 6 High-throughput DNA sequence analysis was used to screen for TET2 mutations in bone marrow-derived DNA as described earlier. A total of 13 TET2 mutations were identified in 11 patients including 8 nonsense and 5 frameshift; these mutations mostly involved exons 4 (n ¼ 8) and 12 (n ¼ 3) (Table 1) . TET2 mutations were seen in 3 (20%) of 15 CMML patients; mutational frequencies were B13 and B29% in our earlier studies with classic BCR-ABL1-negative MPN 2 and SM, 3 respectively. As illustrated in Table 2 , there were no overt differences in the clinical manifestations between TET2 mutated and unmutated CMML patients but a formal statistical comparison was not attempted because of the low numbers involved. However, it is reasonable to mention, without making any conclusions, that all three TET2-mutated CMML patients showed less than 5% bone marrow blasts and one of them developed SM 2 years later. This was also true for the single TET2-mutated MDS patient, out of 16 (6%), who had RARS. Higher proportions of TET2-mutated patients were seen with secondary AML (three of seven patients) and MPN-U (two of four patients), but a much larger study is needed to confirm this trend and clarify its relevance. One of the latter TET2-mutated patients with MPN-U also showed MPLW515L.
One patient each with AML-M3 and MDS/MPN also had mutant TET2. This study illustrates the ubiquitous nature of TET2 mutations across a spectrum of acute and chronic myeloid malignancies. [5] . e 45,XY,add(1)(q32),add(3)(q12),À5,À6,add(7)(q32),À10, add(11)(p13),+13,add(13)(p11.2)x2,À22,+2mar [7] /46,idem,+add(13)(p11.2)[13].
Table 2
Clinical and laboratory features of 16 patients with chronic myelomonocytic leukemia stratified according to their TET2 mutational status Abbreviations: BM, bone marrow; LDH, lactate dehydrogenase.
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The type of TET2 mutations and the specific exons involved in this study were also largely similar to those seen in patients with MPN or SM. 2, 3 Because of the relatively small number of patients included in this study, it is important not to overplay the observed disease-specific mutational frequencies. Furthermore, accurate interpretation of TET2 mutational frequency requires accounting for age; in our earlier report involving patients with BCR-ABL-negative classic MPN (n ¼ 239), 2 overall mutational frequency was 23% in patients X60 years of age versus 4% in younger patients (Po0.0001). 2 In another related study, 3 the corresponding figures in SM (n ¼ 42) were 39 and 13% (P ¼ 0.07). Another interesting observation from this and our earlier reported related studies 2,3 is the fact that mutant TET2 can coexist with other pathogenetically relevant (or potentially relevant) mutations including PML-RARA (this study), MPLW515L (this study), JAK2V617F 2 or KITD816V.
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The above-mentioned observations raise several questions: (i) Considering the ubiquitous nature of mutant TET2 in myeloid malignancies, is it possible that it is also present in lymphoid or other neoplasms? (ii) In instances where mutant TET2 coexists with other mutations, does it predate or postdate their emergence? (iii) Within the context of a specific disease, does the presence of mutant TET2 affect phenotype, prognosis or treatment response? (iv) Is mutant TET2, in those who carry the mutation, a better indicator of clonal response to treatment? (v) What exactly is the pathogenetic contribution of mutant TET2 in myeloid malignancies? It is relatively easy to address the first four questions, but we encourage patience before making any clinical associations until one sees a consistent pattern across studies from different centers. The question that is both most important and difficult to address concerns the precise pathogenetical contribution of mutant TET2 in myeloid neoplasms, especially in view of its occurrence across different molecular profiles.
The type of TET2 mutations seen so far are mostly frameshift or nonsense, and are therefore inactivating. Furthermore, Delhommeau et al. 1 have shown that both copies of the gene were affected in a subset of TET2-mutated MPN patients, and that mutant TET2 was associated with loss-of-heterozygosity/somatic deletion at its 4q24 chromosomal location, suggesting a tumor suppressor function for the wild-type allele. They also showed the occurrence of mutant TET2 in both JAK2V617F-positive and negative clones from otherwise JAK2V617F-positive MPN patients, suggesting that TET2 mutations antedated JAK2V617F during the evolution of the malignant clone, at least in certain instances. In the presence of mutant TET2, as opposed to its absence, the coexisting JAK2V617F-positive clone constituted a higher proportion of the CD34 þ /CD38À cell fraction and showed enhanced engrafting in NOD-SCID mice. Taken together, these observations would suggest that TET2 mutations, although ubiquitous, are not simply passenger mutations and that their acquisition by the malignant clone might enhance its stem cell-like properties without necessarily affecting its differentiating capacity. Additional laboratory studies are needed to further clarify the biological consequence of these mutations. Therapies that are targeted to the molecular genetic defect of malignancies have proven more successful than conventional chemotherapeutic approaches. [1] [2] [3] [4] A broad application of this strategy will require a detailed understanding of the genetic lesions involved in oncogenesis. Tyrosine kinases constitute a gene family of 91 members that play a critical role in numerous cellular processes, and aberrant regulation of tyrosine kinase activity has been observed in numerous types of malignancies. 5 One malignancy in which tyrosine kinases are abnormally
